Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
You've successfully got advanced quotes worth 5000 HKD
Download APP >>

【次新异动】腾盛博药-B(02137)上涨11.49% 近期慢性乙肝2a/2b期临床试验完成首例患者给药

鳳凰網港股 ·  {{timeTz}}


据悉,公司近日发布公告称,公司在慢性乙型肝炎病毒(HBV)患者的BRII-179 (VBI2601) 2a/2b期临床试验中已完成首例患者给药。据估计,全球有2.9亿人患有慢性 HBV感染,且每年有近80万人死于与HBV相关肝硬化、肝衰竭和肝癌等并发症。BRII-179(VBI-2601)是一种新型的基于重组蛋白的HBV免疫治疗候选药物,能够表达Pre-S1、Pre-S2和S乙肝表面抗原,旨在增强B细胞和T细胞免疫。

This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top